scholarly journals Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient

Medicine ◽  
2021 ◽  
Vol 100 (43) ◽  
pp. e27611
Author(s):  
Quentin Dominique Thomas ◽  
Marie Pautas ◽  
Marie-Noëlle Guilhaume ◽  
Fréderic Fiteni ◽  
Tony Ge ◽  
...  
2020 ◽  
Vol 26 (8) ◽  
pp. 2031-2033
Author(s):  
Nilay Sengul Samanci ◽  
Emir Celik ◽  
Burak Akovalı ◽  
Sait Sager ◽  
Fuat Hulusi Demirelli

Introduction Ceritinib is a selective second-generation ALK inhibitor that is highly sensitive to echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) molecule. Case report In this paper, we report a 68-year-old female that was diagnosed with stage 4 ALK-positive non-small cell lung cancer (NSCLC). Management and outcome: She was treated with crizotinib first-line, cisplatin and gemcitabine as second-line. And for third-line, ceritinib was started. She had complete response over 3.5 years under ceritinib treatment. And she is still receiving ceritinib with no adverse event. Discussion Cases achieving complete response with ceritinib treatment are rare. In this paper, we aimed to emphasize the complete response in stage 4 NSCLC in an elderly patient.


2021 ◽  
Vol 16 (4) ◽  
pp. S782
Author(s):  
I. Dogan ◽  
M. Gürbüz ◽  
N. Paksoy ◽  
F. Ferhatoğlu ◽  
S. Vatansever ◽  
...  

2013 ◽  
Vol 8 (12) ◽  
pp. 1570-1573 ◽  
Author(s):  
Justin F. Gainor ◽  
Sai-Hong Ignatius Ou ◽  
Jennifer Logan ◽  
Lawrence F. Borges ◽  
Alice T. Shaw

2017 ◽  
Vol 12 (1) ◽  
pp. S378-S379 ◽  
Author(s):  
Young Kim ◽  
Toyoaki Hida ◽  
Hiroshi Nokihara ◽  
Masashi Kondo ◽  
Koichi Azuma ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document